Prostate cancer affects millions of men every year and is one of the deadliest if not caught quickly. Thankfully, it can be easily treated if it is caught quickly enough, but what baffles many researchers is why this cancer recurs after it has been treated.
A new study by Roswell Park, as reported by Oncotarget, indicates new hope in helping those who suffer from this problem. So if you or a loved one is suffering from prostate cancer and needs a little hope in a difficult time, read on to find out how treatment may be affected.
Read more articles at ImpactJournals.com.
The Standard Treatment Method
Before discussing the Roswell Park study, it is a good idea to understand the way prostate cancer is typically treated. Generally, it is treated by blocking androgen production in men. This male sex hormone is the main cause of prostate cancer and blocking it typically stops it from recurring after the treatment method is over.
However, it is possible for prostate cancer to recur even with this treatment method. Thankfully, it doesn’t occur regularly enough to be a major threat to the health of most men. But it occurs in enough to make it important to find a way to stop it. And Roswell Park may have taken the first step in the right direction.
The incredible breakthroughs reported by Roswell Park found that there is actually an 11-gene signature in recurring cancer tumors that is not prevalent in non-recurring prostate cancer. This major breakthrough makes it possible to test these tumors ahead of time to get a feel for the chance of recurring tumors.
This finding also helps support the idea that it is possible to combine various forms of treatment to combat this problem. Being able to identify potentially recurring tumors earlier in the process will make it possible to use this therapy method earlier and eliminate the chance of rampant recurring tumors.
The importance of this finding cannot be overstated. It could potentially change the way prostate cancer is treated and could even work as a potential cure. Read all about it in the latest issue of Oncotarget to get an idea of what to expect.
Also read journals at DovePress.com.